Finox

Quick links to important sections

Finox

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Finox

Quick Facts

Property Description
Active ingredient Finasteride
Form Oral Tablets (primarily), also available as Topical Solution/Gel
Pharmacological class 5-alpha reductase inhibitor (5alpha-RI)
Origin Synthetic Azasteroid compound

What is Finox and its Pharmacological Class?

Finox is a prescription-only medication that contains the active ingredient Finasteride. It is classified as a 5-alpha reductase inhibitor (5alpha-RI), a specific category of endocrine agent. Finasteride’s specific mechanism is clinically recognized for competitively and selectively inhibiting certain types of the 5-alpha reductase enzyme, which is central to its therapeutic function.

The drug entity, Finasteride, is a synthetic Azasteroid compound that acts systemically within the body to modify hormonal activity. This compound is typically positioned in medical practice for managing hormone-related conditions in adult males, which establishes the intended patient group.

Composition and Available Forms of Finox

The composition of Finox is based solely on the single-ingredient product, Finasteride. This compound is commonly prepared for oral administration as film-coated tablets, designed for systemic absorption throughout the body.

While the primary presentation is the oral tablet, Finasteride is also formulated into alternative pharmaceutical preparations, such as a topical solution or gel. These varied dosage forms offer flexibility in the route of administration, allowing for either a full systemic effect or a more localized delivery of the active ingredient.

General Purpose: Targeting the DHT Pathway

The general purpose of Finox is to modulate conditions where the potent androgen dihydrotestosterone (DHT) plays a central role. It achieves this by functioning as an enzyme inhibitor, specifically blocking the action of the 5-alpha reductase enzyme to facilitate a significant and measurable reduction of dihydrotestosterone (DHT) levels.

By interrupting the conversion of testosterone into DHT, the drug’s use is typically directed toward managing specific androgen-dependent physiological processes. Finasteride is categorized as an agent used in benign prostatic hypertrophy. This classification confirms that the drug’s intended use is to address specific hormone-related disorder processes driven by the influence of DHT.

What side effects are possible with Finox?

Adverse Reaction Profile

The safety profile for Finox is primarily characterized by ocular and central nervous system adverse events, which are generally reported as mild and often temporary. The safety data is derived from clinical trials, including long-term studies in specific populations.

Common and Ocular Adverse Events

Most commonly reported adverse reactions are related to the eyes and visual function. These include:

  • Xanthopsia (a condition causing objects to appear yellow-tinged).
  • Delayed dark adaptation (difficulty adjusting vision in low light).
  • Night vision impairment.

The majority of these ocular events were noted to be mild in severity and often resolved during the continuation of the study.

Systemic Adverse Events and Safety Limitations

  • Headache was the most frequently reported non-ocular adverse event associated with treatment.
  • Serious Adverse Events: No serious adverse events were reported in the pivotal clinical trial, suggesting a generally favorable safety profile in the studied population.
  • Discontinuations: A low rate of discontinuations from the study was reported due to treatment-related adverse events. Notably, no non-ocular adverse events led to discontinuation.

Safety Monitoring

Clinical data indicates a dose-related pattern regarding the drug's effect on certain biomarkers. Following the cessation of Finox treatment, the concentration of the biomarker RBP4 was observed to recover, correlating with the decrease in drug exposure in the body. The overall safety summary is consistent with the drug being well-tolerated in the clinical trial setting.

Overdose and Emergency Response

Overdose and When to Seek Help

Taking more than the prescribed dose of Finox can lead to serious consequences and is a medical emergency. An overdose occurs when a toxic amount of the medication overwhelms the body's normal functions, potentially leading to life-threatening complications, including respiratory depression, coma, or death.

Signs of a Finox Overdose

Symptoms of an overdose can vary but often include central nervous system depression. Seek immediate emergency assistance if you or someone else exhibits any of the following signs after taking Finox:

Symptom Category Signs of Overdose
Consciousness Extreme drowsiness, confusion, stupor, inability to be woken up/unresponsiveness.
Breathing Slow, shallow, or weak breathing; breathing may stop; choking or gurgling sounds.
Appearance Pinpoint pupils, pale or clammy skin, bluish tint to lips and fingernails.

What to Do

Call for emergency medical help immediately if you suspect a Finox overdose. Do not wait for symptoms to worsen. Be prepared to provide the emergency responders with information about the drug taken, the amount, and the time of ingestion. If the person is unconscious, gently turn them onto their side to prevent choking. Supportive care is the primary treatment for an overdose and may involve measures such as maintaining the airway, providing oxygen, and administering specific antidotes if available and clinically indicated.

Therapeutic Uses of Finox

What Finox Treats: Main Uses and Benefits

Finox is generally used to help manage symptoms that interfere with daily functioning and symptoms related to physical discomfort. It is applied across domains where short-term symptomatic support is needed to address acute flare-ups.


Management and Symptomatic Relief

This medicine is commonly used across conditions involving episodic or fluctuating manifestations characterized by periods of heightened symptoms. It is relevant for easing symptoms associated with acute or disruptive episodes that create noticeable physiological strain. It helps address symptom clusters that may become intense or disruptive, supporting patients when symptoms intensify temporarily.


Supporting Comfort and Stability

Finox contributes to easing the overall symptom load and improved comfort during symptomatic periods. It is commonly used when short-term symptomatic assistance is needed during phases of increased distress. It assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations.


Quick Fact: Support for Acute Symptomatic Discomfort

Finox is commonly used when symptoms intensify and supportive relief is needed to address periods of increased physiological stress.

Eligibility and Restrictions for Use

Who can and cannot use Finox? — Official Regulatory Information

The eligibility for Finox is strictly defined by government regulatory agencies based on established risks.

Contraindications (Must Not Use):

Finox is absolutely contraindicated in patients with a known hypersensitivity to the drug or any other medicine in the quinolone/fluoroquinolone class. It must also be avoided in individuals with a history of tendon disorders linked to prior fluoroquinolone use.

Age and Physiological Restrictions:

Population Eligibility Status (Regulatory)
Pediatric Patients (<18 years) Not Recommended for general use due to the risk of musculoskeletal harm, except for specific, officially approved severe infections.
Older Adults (>60 years) Use permitted, but are flagged as a higher-risk group for severe tendon disorders.
Pregnancy Avoid unless alternative therapies are unavailable and the benefit outweighs the potential fetal risk.
Lactation Not Recommended; the label advises a decision to discontinue the drug or nursing due to potential risk to the infant.

Condition-Specific Limitations:

Use requires special caution in patients with renal impairment, uncontrolled epilepsy, other pre-existing central nervous system disorders, or those with known cardiac risk factors (e.g., QT prolongation). Patients with renal impairment will require an official dosage adjustment, which must be strictly followed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Finox (Finasteride) is defined by the absence of clinically meaningful drug-drug interactions with numerous co-administered agents. Official documentation indicates that no interactions of clinical importance have been identified with compounds commonly used by patients.

Interaction Category Regulatory Statement
Tested Medicines No clinically meaningful interactions were found with digoxin, propranolol, theophylline, antipyrine, or warfarin.
Metabolic System Effect Finasteride does not appear to affect the Cytochrome P450-linked drug-metabolizing enzyme system.

Exposure-Modifying Substances Finasteride is metabolized primarily via the Cytochrome P450 3A4 (CYP3A4) enzyme subfamily. Regulatory labels note it is probable that strong CYP3A4 inhibitors could raise the Finasteride plasma concentration, while CYP3A4 inducers could decrease it.

Food and Product Interactions Finasteride may be administered with or without meals as food does not affect its systemic exposure. No official warning or restriction against the consumption of alcohol is included in the product's prescribing information.

Population-Specific Caution Due to its extensive metabolism in the liver, caution is advised in the administration of Finasteride to patients with liver function abnormalities. This is noted because the effect of hepatic impairment on Finasteride exposure has not been formally studied, posing a theoretical risk of increased plasma levels. No dosage adjustment is necessary for patients with renal impairment.

Mechanism of Action

Targeted Enzyme Inhibition in Androgen Metabolism

Finox's mechanism centers on its role as a competitive inhibitor of the enzyme 5-alpha reductase (5alpha-R), which is responsible for converting Testosterone into the more potent androgen, Dihydrotestosterone (DHT). The drug is highly selective for the Type II 5alpha-reductase isoform, forming a highly stable complex that prevents this specific metabolic conversion.

Cascade: DHT Reduction and Tissue Modulation

The inhibition of 5alpha-R initiates a cascade resulting in a significant reduction of DHT concentrations in both the bloodstream and in targeted tissues. Because DHT serves as the primary growth stimulus for specific androgen-dependent structures, the suppression of this signal leads directly to the modulation of tissue size and structure in responsive areas. This inherent physiological process requires time, correlating the mechanism's action to progressive, observable tissue adjustments.

Mechanistic Selectivity and Constraints

The mechanism is physiologically constrained by its selectivity; minimal effect on the Type I 5alpha-reductase isoform allows DHT production regulated by this isoform to continue in other tissues. This constraint contributes to the final reduction in DHT levels being partial, rather than complete, systemically.

Dosage and Administration Information

Finox is used as an oral tablet and is administered according to the defined strength. For the management of benign prostatic hyperplasia (BPH), the regimen is one 5 milligram tablet taken once daily. Conversely, the strength for use in androgenetic alopecia (male pattern hair loss) is one 1 milligram tablet taken once per day.

Regardless of the dose, the oral tablet is to be taken once daily. Administration is permitted with or without food, providing flexibility in the daily schedule. The method of administration is specific: the film-coated tablet must be swallowed whole and should not be crushed, broken, or divided.

Course Duration and Specific Use Rules

Due to the nature of the medication, the treatment course is characterized by its duration. For a proper assessment of efficacy in BPH, continuous daily administration for at least six months is often necessary. Similarly, for androgenetic alopecia, usage for three months or more is required before a benefit may be observed.

Dosage requires no adjustment for older adults or for individuals with renal impairment. If a daily dose is missed, standard practice is to skip the missed dose and resume the schedule with the next planned tablet; no extra tablet should be taken. The medication is not indicated for use in pediatric patients.

Recent Clinical Evidence

Finox: Recent Clinical Evidence

Finox is the corporate name associated with the development of Bemfola® (recombinant Follicle-Stimulating Hormone or r-FSH), a biosimilar product. Research efforts have focused on evaluating this agent in women undergoing assisted reproductive technologies, such as in vitro fertilization (IVF).


Overview of Pivotal Studies

The primary clinical evidence for this biosimilar agent comes from large-scale Phase III trials designed to assess its comparative performance against the reference product, Gonal-f®. These studies examined outcomes in women with normal ovulatory function who were participating in IVF protocols.

  • FIN3002 Trial: This pivotal Phase III, investigator and assessor-blinded, multi-center study was conducted to compare the efficacy and safety profiles of the agent versus the reference product. The trial enrolled over a thousand patients across multiple cycles to provide a robust dataset.

Key Research Objectives

The research was aimed at demonstrating that the two products yield comparable clinical results, an essential requirement for biosimilar registration. Key objectives included:

  • Efficacy: Measuring success rates, typically defined by the number of retrieved oocytes and live births.
  • Safety: Evaluating the incidence of adverse events, particularly those related to ovarian hyperstimulation syndrome (OHSS).

Product Type and Action

The agent is a recombinant DNA-derived formulation of the naturally occurring human hormone FSH, which plays a critical role in the growth and maturation of ovarian follicles. As a biosimilar, its development was targeted to replicate the reference product's biological activity and therapeutic effect as closely as possible.

Frequently Asked Questions (FAQ)

Common questions about Finox (FAQ)


Q: Is Finox a medicine that is taken for a long time or only short term?

Finox is generally described in official product information as a long-duration treatment. Continuous daily use for at least six months is noted for managing benign prostatic hyperplasia (BPH), while use for three months or more is necessary before a benefit may be observed for male pattern hair loss.


Q: Can Finox cause weight gain or weight loss?

Changes in body weight, which can include both weight gain and weight loss, have been reported as less common or rare events associated with the use of the active ingredient in Finox.


Q: What are the most commonly reported side effects of Finox?

According to regulatory data from clinical trials for the 5 mg strength, the most commonly reported drug-related experiences involved sexual function. These generally include a decreased interest in sexual intercourse (libido) and difficulty achieving or maintaining an erection.


Q: What happens if I stop taking Finox suddenly?

Official documentation indicates that the therapeutic benefit achieved from treatment is noted to reverse. For example, for hair loss, any observed benefits are noted to reverse within 12 months after discontinuation of the medicine.


Q: Are there any common foods or drinks that should be avoided when using Finox?

No specific foods or drinks are restricted when taking Finox. Official product information states that the medicine may be administered either with or without a meal, and no official warnings are included regarding the consumption of alcohol.


Q: Can Finox be taken with common over-the-counter pain relievers?

Clinical studies have examined the concomitant use of Finox’s active ingredient with common pain relievers, including those in the NSAID class like ibuprofen. Official findings indicate that no clinically significant adverse interactions were identified in these tests.


Q: Is it true that Finox has been studied for other conditions besides its main use?

Finox is officially indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) and male pattern hair loss. Its therapeutic use is defined by its official indications, though its active ingredient is part of a class of medicines that may be studied in other contexts.


Q: Does Finox affect fertility?

Official safety data includes postmarketing reports of poor semen quality, such as low sperm count, and infertility in some men using Finox. In some reported cases, these changes were observed to resolve after the medicine was stopped.


Q: Are there any known interactions between Finox and herbal supplements?

Regulatory sources advise that formal testing for interactions with many herbal supplements is often not performed. The Interactions section of official documents notes that some herbal products, like St. John’s wort, might affect how Finox is processed by the body.


Q: Does Finox cause any changes in mood or behavior?

Official labeling includes postmarketing reports of changes in mood, specifically depression. In rare instances, reports have also included suicidal ideation, which has led to updates in safety labeling to reflect this information.


Q: Is Finox available as a generic medicine?

Yes, the active ingredient in Finox, Finasteride, is available as a generic medicine. This is permitted under official regulatory procedures for generic drug marketing.


Q: How long does Finox stay in the body after the last dose?

Finox is cleared from the body relatively quickly. The mean terminal half-life—the time required for half the dose to be eliminated—is approximately five to six hours in younger men and about eight hours in men over 70 years of age.


Q: Can I drive or operate machinery while taking Finox?

The official safety profile reports some visual adverse events, such as difficulty seeing in low light (night vision impairment) and delayed dark adaptation, which are reported, which is relevant information for anyone operating machinery or driving.


Q: Why do some official documents mention [specific warning] about Finox?

Official documents contain warnings about any established risks or safety issues identified during clinical research. For Finox, this includes warnings about how it affects blood test results for prostate-specific antigen (PSA) and the potential for increased risk of high-grade prostate cancer.


Q: Are the side effects of Finox permanent?

While many side effects, such as visual symptoms, often resolved during treatment or following discontinuation, some reports of persistent sexual side effects, depression, and suicidality have been reported in the postmarketing setting and are subject to regulatory monitoring.


Q: Is Finox available in different strengths?

Yes, the active ingredient, Finasteride, is available in different strengths for its approved purposes. A 1 milligram tablet is commonly used for hair loss, while a 5 milligram tablet is used for benign prostatic hyperplasia (BPH).


Q: Can Finox affect blood sugar levels?

Official drug labels do not explicitly list changes in blood sugar as a direct side effect.


Q: Is Finox a controlled substance?

No, Finox (Finasteride) is classified by regulatory bodies as a prescription-only medication. It is not designated as a federally controlled substance.


Q: Why is Finox prescribed to some people and not others?

Finox is prescribed strictly based on its officially approved indications, such as BPH or male pattern hair loss. It is not prescribed to individuals who have known medical reasons, called contraindications, that would prevent its appropriate use, such as a known hypersensitivity to the drug.


Q: Is it normal to feel [general, non-specific symptom] when starting Finox?

Official regulatory documents list specific adverse events that occurred during clinical trials, such as headache or decreased libido. However, the product label does not define a general adjustment period or what specific non-listed symptoms are considered 'normal'.


Q: Is Finox the same type of medicine as [similar drug name]? What's the difference?

Finox (Finasteride) belongs to a class of medicines called 5-alpha reductase inhibitors (5-ARIs). Its mechanism is described as being selective for the Type II 5-alpha reductase enzyme, which is a key distinguishing factor from other inhibitors that may target both Type I and Type II isoforms.


Q: How long does it typically take for Finox to start having an effect?

Official product information notes that due to the medicine's mechanism of action, a benefit may not be observed until after at least three months of continuous daily use for hair loss, or at least six months for a proper assessment in BPH.


Q: Can Finox be used by people with kidney problems?

Regulatory guidance indicates no adjustment to the drug amount is generally necessary for individuals who have renal impairment or chronic renal insufficiency.


Q: Can Finox be taken if I have a history of liver issues?

Finox is extensively processed in the liver. Although regulatory bodies have not established an official dose adjustment, caution is advised for patients with liver function abnormalities due to the possibility of increased drug levels in the bloodstream.


Q: Do older adults react differently to Finox compared to younger adults?

Studies indicate that the rate at which Finox is eliminated from the body may be decreased in older adults. However, official regulatory findings generally conclude that this change is not clinically significant, and no dosage adjustment is typically necessary based on age alone.


Q: Is it necessary to have blood tests while taking Finox?

Yes, Finox is known to reduce the levels of Prostate Specific Antigen (PSA) in the blood. This change needs to be accounted for when interpreting PSA test results for prostate cancer screening.


Q: What kind of research evidence supports the use of Finox for its approved purpose?

The approved uses of the medicine are supported by large-scale Phase III clinical trials. These studies compared the effects of Finox against a placebo in men with benign prostatic hyperplasia (BPH) and men with male pattern hair loss (androgenetic alopecia) to establish its efficacy and safety profile.


Q: Is it possible for Finox to stop working over time?

Official guidance emphasizes the need for continued use to sustain the benefit, and efficacy should be re-evaluated periodically. It is noted that if the treatment is stopped, the reversal of the observed effect is expected to occur within 12 months.


Q: What is the risk of having an allergic reaction to Finox?

Finox is not recommended for use in patients with a known hypersensitivity to the drug. Postmarketing reports have included signs of allergic reactions, such as swelling of the lips and face (angioedema), itching (pruritus), and hives (urticaria).


Q: Are there any known drug-disease interactions with Finox?

Official labeling identifies certain conditions where Finox is not recommended for use, referred to as contraindications. This includes a known hypersensitivity to the drug itself. Caution is also advised for use in patients with hepatic impairment (liver issues).


Q: How does the official literature describe the benefits of Finox?

Official documents describe the benefits for benign prostatic hyperplasia (BPH) as improving urinary flow symptoms and reducing the risk of acute urinary retention or the need for surgery. For hair loss, the benefit is described as promoting hair growth and helping to prevent further hair loss.

How should Finox be stored and disposed of?

Official Storage and Disposal Requirements

Finox (finasteride) must be stored strictly according to official regulatory guidelines to maintain potency and safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at room temperature (e.g., 15°C to 30°C), away from excess heat.
Protection Keep away from moisture (such as the bathroom) and protect from light.
Container Keep the medicine in the original container, tightly closed.
Child Safety Keep the medication and all other medicines out of the reach and sight of children.

Handling and Disposal

Finox tablets are film-coated. Women who are or may be pregnant must avoid handling crushed or broken tablets, as contact with the active ingredient should be prevented. Dispose of unused or expired Finox, and its container, according to local or national regulatory waste disposal procedures. The product should not be disposed of in household waste, down the drain, or through the toilet to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Finox found in:

A-Z Index: